0001708138-22-000020.txt : 20220318
0001708138-22-000020.hdr.sgml : 20220318
20220318160521
ACCESSION NUMBER: 0001708138-22-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220316
FILED AS OF DATE: 20220318
DATE AS OF CHANGE: 20220318
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tessier-Lavigne Marc
CENTRAL INDEX KEY: 0001437435
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19034
FILM NUMBER: 22752508
MAIL ADDRESS:
STREET 1: 1 DNA WAY
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENERON PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000872589
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133444607
STATE OF INCORPORATION: NY
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
BUSINESS PHONE: 9148477000
MAIL ADDRESS:
STREET 1: 777 OLD SAW MILL RIVER ROAD
CITY: TARRYTOWN
STATE: NY
ZIP: 10591
FORMER COMPANY:
FORMER CONFORMED NAME: REGENERON PHARMACEUTICALS INC
DATE OF NAME CHANGE: 19930328
4
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4
2022-03-16
0
0000872589
REGENERON PHARMACEUTICALS, INC.
REGN
0001437435
Tessier-Lavigne Marc
777 OLD SAW MILL RIVER ROAD
TARRYTOWN
NY
10591
1
0
0
0
Common Stock
2022-03-16
4
M
0
4361
374.12
A
6630
D
Common Stock
2022-03-16
4
S
0
4361
675.0
D
2269
D
Common Stock
2022-03-17
4
M
0
7830
376.69
A
10099
D
Common Stock
2022-03-17
4
S
0
7830
680.0
D
2269
D
Non-Qualified Stock Option (right to buy)
374.12
2022-03-16
4
M
0
4361
0.0
D
2030-01-02
Common Stock
4361
0
D
Non-Qualified Stock Option (right to buy)
376.69
2022-03-17
4
M
0
7830
0.0
D
2027-01-03
Common Stock
7830
0
D
Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that had passed from the date of grant became exercisable, and the remainder became exercisable on the first anniversary of the date of grant.
The stock option becomes exercisable in three equal annual installments, commencing one year after the date of grant.
/s/**Marc Tessier-Lavigne
2022-03-18